Melanoma treatment shows promise

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *